VALIDATE is an international network of Vaccine researchers who are focused on four pathogens that cause diseases that have significant impact on low and middle-income countries including tuberculosis, leishmaniasis, melioidosis and leprosy.

Our seminars highlight some of the important research being undertaken by our extensive community of researchers. We will put details of any upcoming seminars on this page.

Members can watch some of our seminars by first logging on to WebLearn and then clicking here.

VALIDATE Online Summer Seminars

Due to the COVID-19 pandemic, we are able to arrange in-person seminars. However, have been busy organising a series of Online Summer Seminars that will highlight some of the amazing work being done by our members.




Seminar Archive

Expand All

Developing a vaccine for Melioidosis: Probing the protective immune response

Location: Online via Zoom.

Date: 30 June 2020

​​Time: 15:00 BST - 16:00


Prof Siobhán McClean is an Associate Professor at School of Biomolecular and Biomedical Science, UCD.  Prof McClean has a research interest in host pathogens associated with respiratory pathogens that cause opportunistic infections and in identifying vaccine antigens that are protective against Burkholderia pseudomallei.

Dr Julen Tomás Cortázar is a postdoctoral researcher at UCD. He is leading part of a project funded by Wellcome Trust agency to develop a vaccine against Melioidosis caused by the Gram-negative bacteria Burkholderia pseudomallei.

Watch the Seminar: Members can watch first logging on to WebLearn and then clicking here.




andrea cooper seminar

VALIDATE Network Managment Board member Prof Andrea Cooper delivered this seminar on 15 Jan 2020 at the Jenner Institute, and has kindly agreed for us to share it with all VALIDATE members. 

Members can watch the seminar on Panopto.


VALIDATE seminar - Developing a better vaccine against TB

This seminar took place 15 February 2019 and was led by Prof Helen McShane and Dr Rachel Tanner.

TB kills more people than any other infectious disease. The efficacy of the only available vaccine, BCG, is highly variable and lowest in high burden settings. The McShane group is developing novel TB vaccine candidates by identifying novel antigenic targets and exploring novel routes of immunization.

TB vaccine development is challenging given the lack of defined immunological correlates of protection. Class II restricted T cells are critical for protective immunity but may not be sufficient. Dr Tanner provided an update on functional mycobacterial growth inhibition assays and on a role for antibodies in protective immunity.

Members can watch the seminar on Panopto.

zelmer fletcher seminar

This seminar took place on the 6 December 2017 at LSHTM and was led by Dr Andrea Zelmer and Dr Helen Fletcher, LSHTM.

Immune correlates of risk of TB disease have recently been identified in human clinical trials.  These correlates indicate that, years before TB disease develops, there is alteration in the host-immune environment which is associated with risk of TB disease. Perhaps these alterations render the immune environment permissive to mycobacterial infection or increased growth, or perhaps they reduce the efficacy of the BCG vaccine?  Back translation of immune correlates of risk into animal models will enable us to address these questions and model the immune response of those individuals at greatest risk of TB disease.

Members can watch the seminar on Panopto